Agenda

Showcasing a curated group of high-potential companies developing the next generation of therapeutic assets, diagnostics, biomarkers, and precision tools for women's health. Six selected finalists will present clinically grounded, commercially relevant innovations in a rapid-fire format to an audience of pharmaceutical leaders, investors, CROs, and strategic partners across the women's health ecosystem. The session is designed to surface differentiated science, highlight emerging approaches to targeting and treatment, and demonstrate how therapeutics and precision tools are increasingly being developed together to improve outcomes, reduce risk, and enable more personalised care. Finalists gain visibility with senior decision-makers across pharma, diagnostics, clinical development, and healthcare, while contributing to a broader view of how the women's health pipeline is evolving toward more targeted, data-driven, and effective interventions.

Format: ' 6 finalist companies ' 7-minute presentation per company ' 2-minute moderated Q&A with expert judges ' Audience and Judges' Choice winners announced at the end of the day Finalists will be selected based on: ' strength and differentiation of the therapeutic or precision approach ' level of clinical or translational validation ' relevance to unmet need in women's health potential to improve targeting, outcomes, and real-world impact.

Judges:

Stasia Obremskey, Managing Partner, Foreground Capital

Mané Mikayelyan, Associate Partner, DeciBio Consulting

Karla Loken, Founder, Loken & Associates

Parambir Bhangu, Executive Director, External Innovation & Emerging Science, Organon